HCC Monitor
September 2016
Volume: 2
Issue: 3
June 2016
Volume: 2
Issue: 3
April 2016
Volume: 2
Issue: 1
October 2015
Volume: 1
Issue: 3
July 2015
Volume: 1
Issue: 2
April 2015
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5